ZA982517B - Novel inhibitors of the formation of soluble CD23 in humans. - Google Patents
Novel inhibitors of the formation of soluble CD23 in humans.Info
- Publication number
- ZA982517B ZA982517B ZA9802517A ZA982517A ZA982517B ZA 982517 B ZA982517 B ZA 982517B ZA 9802517 A ZA9802517 A ZA 9802517A ZA 982517 A ZA982517 A ZA 982517A ZA 982517 B ZA982517 B ZA 982517B
- Authority
- ZA
- South Africa
- Prior art keywords
- humans
- soluble
- formation
- novel inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9706255.8A GB9706255D0 (en) | 1997-03-26 | 1997-03-26 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA982517B true ZA982517B (en) | 1999-09-27 |
Family
ID=10809882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9802517A ZA982517B (en) | 1997-03-26 | 1998-03-25 | Novel inhibitors of the formation of soluble CD23 in humans. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6242467B1 (es) |
| EP (1) | EP0973732A2 (es) |
| JP (1) | JP2001518922A (es) |
| KR (1) | KR20010005627A (es) |
| CN (1) | CN1251091A (es) |
| AR (1) | AR012294A1 (es) |
| AU (1) | AU7210598A (es) |
| BR (1) | BR9808366A (es) |
| CA (1) | CA2285439A1 (es) |
| CO (1) | CO4950563A1 (es) |
| GB (1) | GB9706255D0 (es) |
| HU (1) | HUP0003021A3 (es) |
| IL (1) | IL131751A0 (es) |
| NO (1) | NO994671D0 (es) |
| PL (1) | PL336039A1 (es) |
| TR (1) | TR199902357T2 (es) |
| WO (1) | WO1998042659A2 (es) |
| ZA (1) | ZA982517B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5904697A (en) * | 1995-02-24 | 1999-05-18 | Heartport, Inc. | Devices and methods for performing a vascular anastomosis |
| IL134273A0 (en) * | 1997-07-31 | 2001-04-30 | Procter & Gamble | Acyclic metalloprotease inhibitors |
| US6403632B1 (en) * | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
| BR0007784A (pt) | 1999-01-27 | 2002-02-05 | American Cyanamid Co | Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto |
| US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
| US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6566381B1 (en) | 1999-03-03 | 2003-05-20 | The Procter & Gamble Company | Hetero-substituted metalloprotease inhibitors |
| WO2000051975A1 (en) | 1999-03-03 | 2000-09-08 | The Procter & Gamble Company | Alkenyl- and alkynyl-containing metalloprotease inhibitors |
| GB9922825D0 (en) * | 1999-09-25 | 1999-11-24 | Smithkline Beecham Biolog | Medical use |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| AU2001233965A1 (en) * | 2000-02-24 | 2001-09-03 | Smithkline Beecham Plc | Novel cd23 inhibitors |
| US20040024066A1 (en) * | 2000-05-25 | 2004-02-05 | Best Desmond John | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides |
| YU103003A (sh) | 2001-06-26 | 2006-05-25 | Abgenix Inc. | Antitela za opgl |
| EP1440057A1 (en) | 2001-11-01 | 2004-07-28 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| GB0128376D0 (en) * | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel compounds |
| JP2005512743A (ja) * | 2001-12-27 | 2005-05-12 | エルジー エレクトロニクス インコーポレーテッド | 洗濯機 |
| PT1511472E (pt) | 2002-05-29 | 2009-07-24 | Merck & Co Inc | Compostos úteis no tratamento de antrax e inibição do factor letal |
| US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
| CN1950354A (zh) | 2004-05-11 | 2007-04-18 | 默克公司 | N－磺酰化－氨基酸衍生物的制备方法 |
| ES2549187T3 (es) * | 2008-07-14 | 2015-10-23 | Novartis Ag | Inhibidores selectivos de MMP-12 y MMP-13 basados en ácido hidroxámico |
| USD810196S1 (en) * | 2015-04-14 | 2018-02-13 | Marcia D. Fackler | Sunglass book cover |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5962529A (en) | 1994-06-22 | 1999-10-05 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| GB9414157D0 (en) | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Medical use |
| KR100231230B1 (ko) * | 1995-08-08 | 1999-11-15 | 우에노 도시오 | 히드록삼산 유도체(hydroxamic acid derivatives) |
| BR9609883A (pt) * | 1995-08-08 | 1999-03-23 | Fibrogen Inc | Composto tendo efeito inibidor em proteinase c composição farmacéutica e processo para tratar doenças relacionadas com a produção inapropriada ou desregulada de colágeno |
| JP2000511175A (ja) * | 1996-05-17 | 2000-08-29 | ワーナー―ランバート・コンパニー | ビフェニルスルホンアミドマトリックスメタロプロテイナーゼ阻害剤 |
| CA2256716A1 (en) | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Matrix metalloproteinase inhibitors and their therapeutic uses |
-
1997
- 1997-03-26 GB GBGB9706255.8A patent/GB9706255D0/en active Pending
-
1998
- 1998-03-16 AU AU72105/98A patent/AU7210598A/en not_active Abandoned
- 1998-03-16 WO PCT/EP1998/001766 patent/WO1998042659A2/en not_active Application Discontinuation
- 1998-03-16 KR KR1019997008694A patent/KR20010005627A/ko not_active Application Discontinuation
- 1998-03-16 JP JP54489898A patent/JP2001518922A/ja active Pending
- 1998-03-16 CA CA002285439A patent/CA2285439A1/en not_active Abandoned
- 1998-03-16 US US09/381,405 patent/US6242467B1/en not_active Expired - Fee Related
- 1998-03-16 IL IL13175198A patent/IL131751A0/xx unknown
- 1998-03-16 HU HU0003021A patent/HUP0003021A3/hu unknown
- 1998-03-16 EP EP98919153A patent/EP0973732A2/en not_active Withdrawn
- 1998-03-16 TR TR1999/02357T patent/TR199902357T2/xx unknown
- 1998-03-16 BR BR9808366-0A patent/BR9808366A/pt not_active Application Discontinuation
- 1998-03-16 PL PL98336039A patent/PL336039A1/xx unknown
- 1998-03-16 CN CN98803639A patent/CN1251091A/zh active Pending
- 1998-03-24 AR ARP980101342A patent/AR012294A1/es unknown
- 1998-03-25 ZA ZA9802517A patent/ZA982517B/xx unknown
- 1998-03-26 CO CO98016978A patent/CO4950563A1/es unknown
-
1999
- 1999-09-24 NO NO994671A patent/NO994671D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2285439A1 (en) | 1998-10-01 |
| KR20010005627A (ko) | 2001-01-15 |
| GB9706255D0 (en) | 1997-05-14 |
| WO1998042659A2 (en) | 1998-10-01 |
| EP0973732A2 (en) | 2000-01-26 |
| US6242467B1 (en) | 2001-06-05 |
| AU7210598A (en) | 1998-10-20 |
| PL336039A1 (en) | 2000-06-05 |
| AR012294A1 (es) | 2000-10-18 |
| TR199902357T2 (xx) | 2000-05-22 |
| CO4950563A1 (es) | 2000-09-01 |
| BR9808366A (pt) | 2000-05-23 |
| HUP0003021A3 (en) | 2002-02-28 |
| CN1251091A (zh) | 2000-04-19 |
| HUP0003021A2 (hu) | 2002-01-28 |
| WO1998042659A3 (en) | 1999-02-25 |
| JP2001518922A (ja) | 2001-10-16 |
| NO994671L (no) | 1999-09-24 |
| IL131751A0 (en) | 2001-03-19 |
| NO994671D0 (no) | 1999-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA982517B (en) | Novel inhibitors of the formation of soluble CD23 in humans. | |
| ZA98376B (en) | Sulfamide-metalloprotease inhibitors | |
| GB2346877B (en) | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | |
| ZA200006577B (en) | Phthalazine derivatives as phosphodiesterase 4 inhibitors. | |
| GB2321641B (en) | Sulfamide-metalloprotease inhibitors | |
| ZA977969B (en) | Reflux inhibitors. | |
| PL340727A1 (en) | Benzothiazolic inhibitors of proteinous thyrosinic kinase | |
| IL133368A0 (en) | Urokinase inhibitors | |
| AU2274299A (en) | Benzazine derivatives phosphodiesterase 4 inhibitors | |
| HK1039124A1 (en) | Phthalzaine derivatives phosphodiesterase 4 inhibitors. | |
| AU6882598A (en) | Protein kinase inhibitor | |
| PL353214A1 (en) | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors | |
| GC0000142A (en) | An inhibitor of the formation of soluble human cd23. | |
| GB9815925D0 (en) | HIV Intergrase inhibitors | |
| GB9726750D0 (en) | Camping aid | |
| AU2003200717B8 (en) | Cyclin-dependent kinase inhibitors and uses thereof | |
| AU2003200717A1 (en) | Cyclin-dependent kinase inhibitors and uses thereof | |
| IL141772A0 (en) | Heteroaromatic inhibitors of fructose 1,6-bisphosphatase | |
| GB9727371D0 (en) | Inhibitors | |
| GB9709064D0 (en) | Inhibitors | |
| GB9703335D0 (en) | Inhibitors | |
| GB9713709D0 (en) | Inhibitors | |
| GB9725783D0 (en) | Inhibitors | |
| PT986382E (pt) | Inibidores de raf-quinase | |
| ZA994640B (en) | The tracking of explosives. |